Literature DB >> 19349954

Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children.

N Nishio1, H Yagasaki, Y Takahashi, H Muramatsu, A Hama, M Tanaka, N Yoshida, N Watanabe, K Kudo, A Yoshimi, S Kojima.   

Abstract

Late-onset non-infectious pulmonary complications (LONIPCs) that arise beyond 3 months after allogeneic hematopoietic SCT include bronchiolitis obliterans (BO), bronchiolitis obliterans with organizing pneumonia (BOOP) and idiopathic pneumonia syndrome (IPS). We retrospectively analyzed the incidence and outcome of LONIPCs among pediatric hematopoietic SCT recipients. We included 97 patients who survived for more than 3 months among the 114 who underwent allogeneic hematopoietic SCT between April 1997 and May 2007. Of the 97 enrolled patients, 10 (10.3%) developed LONIPCs at a median of 187 days after hematopoietic SCT (range, 123-826 days). Of the 10 patients with LONIPCs, eight had BO and two had IPS. Multivariate analysis showed that the onset of LONIPCs was associated with high-risk underlying disease and extensive chronic GVHD (hazard ratio, 5.42 (95% confidence interval, 1.36-21.7) and hazard ratio, 11.7 (95% confidence interval, 2.40-57.1), respectively). Only two patients responded to therapy with steroids and six of the 10 patients died. The 5-year OS rate was significantly lower among patients with, than without LONIPCs (28.0 vs 87.2%, P=0.000). Considering that we are lacking optimal therapies for LONIPCs, strategies aimed at the prevention of LONIPCs should be attempted.

Entities:  

Mesh:

Year:  2009        PMID: 19349954     DOI: 10.1038/bmt.2009.33

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  16 in total

Review 1.  How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

2.  Pulmonary Clinicopathological Correlation after Allogeneic Hematopoietic Stem Cell Transplantation: An Autopsy Series.

Authors:  Lee Gazourian; Laura Spring; Emily Meserve; David Hwang; Alejandro A Diaz; Samuel Y Ash; Vincent T Ho; Lynette M Sholl; George R Washko
Journal:  Biol Blood Marrow Transplant       Date:  2017-06-28       Impact factor: 5.742

3.  Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.

Authors:  Kirsten M Williams; Guang-Shing Cheng; Iskra Pusic; Madan Jagasia; Linda Burns; Vincent T Ho; Joseph Pidala; Jeanne Palmer; Laura Johnston; Sebastian Mayer; Jason W Chien; David A Jacobsohn; Steven Z Pavletic; Paul J Martin; Barry E Storer; Yoshihiro Inamoto; Xiaoyu Chai; Mary E D Flowers; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-22       Impact factor: 5.742

4.  Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group.

Authors:  Nobuharu Fujii; Koichi Nakase; Shoji Asakura; Keitaro Matsuo; Yuichiro Nawa; Kazutaka Sunami; Hisakazu Nishimori; Ken-Ichi Matsuoka; Eisei Kondo; Yoshinobu Maeda; Katsuji Shinagawa; Masamichi Hara; Mitsune Tanimoto
Journal:  Int J Hematol       Date:  2014-03-15       Impact factor: 2.490

5.  NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT.

Authors:  K M Williams; O Hnatiuk; S A Mitchell; K Baird; S M Gadalla; S M Steinberg; J Shelhamer; A Carpenter; D Avila; T Taylor; L Grkovic; D Pulanic; L E Comis; B Blacklock-Schuver; R E Gress; S Z Pavletic
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

6.  Lung evaluation in 10 year survivors of pediatric allogeneic hematopoietic stem cell transplantation.

Authors:  Sophie L'excellent; Karima Yakouben; Christophe Delclaux; Jean-Hugues Dalle; Véronique Houdouin
Journal:  Eur J Pediatr       Date:  2019-09-04       Impact factor: 3.183

7.  Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children.

Authors:  H Sano; R Kobayashi; A Iguchi; D Suzuki; K Kishimoto; K Yasuda; K Kobayashi
Journal:  Bone Marrow Transplant       Date:  2013-08-19       Impact factor: 5.483

8.  Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

Authors:  Jeanne Palmer; Kirsten Williams; Yoshihiro Inamoto; Xiaoyu Chai; Paul J Martin; Linus Santo Tomas; Corey Cutler; Daniel Weisdorf; Brenda F Kurland; Paul A Carpenter; Joseph Pidala; Steven Z Pavletic; William Wood; David Jacobsohn; Sally Arai; Mukta Arora; Madan Jagasia; Georgia B Vogelsang; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-04       Impact factor: 5.742

Review 9.  Pediatric lung transplantation: indications and outcomes.

Authors:  Stephen Kirkby; Don Hayes
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

10.  Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation.

Authors:  X Liu; Z Yue; J Yu; E Daguindau; K Kushekhar; Q Zhang; Y Ogata; P R Gafken; Y Inamoto; A Gracon; D S Wilkes; J A Hansen; S J Lee; J Y Chen; S Paczesny
Journal:  Am J Transplant       Date:  2016-03-14       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.